MedLife announces its financial results for the first nine months of 2026, reporting pro-forma consolidated revenue of 2.64 billion lei, up approximately 12% compared to the same period last year. In terms of operating profitability, pro-forma EBITDA reached 398.7 million lei, corresponding to a margin of 16.7% of net sales.
The clinic network contributed nearly 39% of revenue, supported by approximately 4 million visits, while the hospital segment accounted for about 27% of the business. The laboratories, in turn, made significant contributions, accounting for approximately 11% of revenue, with nearly 9 million tests processed in the first nine months of 2026.
“The first nine months of the year confirm the demand and MedLife’s ability to continue growing organically, even in an economic environment characterized by caution and cost pressures. Growth through acquisitions was lower, primarily due to the desire to maintain a prudent level of debt. However, it is possible that we will resume the growth rates of previous years—20%—by doubling our current organic efforts with acquisitions,” said Mihai Marcu, CEO and Chairman of the Board of the MedLife Group.
Looking ahead to the next stage of development, MedLife intends to continue strengthening its position locally through investments in technology and medical infrastructure, as well as through selective acquisitions, while simultaneously exploring opportunities for expansion through acquisitions in Central and Southeastern European markets.
In this context, the Group has announced that it is exploring ways to diversify its financing instruments to provide the flexibility needed to support its growth plans. Among the options under consideration is a potential capital increase through the issuance of new shares, intended to finance organic growth projects, investments in technology, and market consolidation opportunities.
At the same time, MedLife aims to establish, in partnership with a leading international financial institution, a regional investment platform focused on health, beauty, and wellness, with a 3- to 5-year implementation timeline. The initiative could facilitate access to capital and additional expertise, supporting gradual expansion into Central and Eastern Europe, with a priority on the Balkan region. This expansion could take place through acquisitions, greenfield investments, and partnerships, depending on the opportunities identified and the Group’s profitability criteria.
